Abstract
ejd.2013.1991 Auteur(s) : Axel Patrice Villani, Daniela Zaharia, Stephane Dalle, Laurianne Depaepe, Brigitte Balme, Luc Thomas luc.thomas@chu-lyon.fr Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud, 69495 Pierre Benite Cedex, France Vemurafenib, the first selective BRAF inhibitor, is indicated to treat patients with unresectable or metastatic melanoma with the BRAFV600E mutation [1]. This drug is associated with remarkable dermatological adverse effects (skin rash, photosensitivity, squamous-cell [...]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
